

FDA Home³ Medical Devices⁴ Databases⁵

Class 2 Device Recall NeuViz 64
6 510(k)|DeNovo8| Registration &

Adverse

|Recalls¹¹|PMA¹²|HDE¹³|Classification¹⁴|Standards¹⁵

Listing⁹


Events¹⁰

CFR Title 21¹⁶|Radiation-Emitting Products¹⁷|X-Ray Assembler¹⁸|Medsun Reports¹⁹|CLIA²⁰|TPLC²¹

New Search

Back to Search Results

Class 2 Device Recall NeuViz 64



Date Initiated by Firm

August 31, 2016

Create Date

December 23, 2016

Recall Status¹

Open³, Classified

Recall Number

Z-0875-2017

Recall Event ID

75383²³

510(K)Number

K121792²⁴

Product Classification

System, x-ray, tomography, computed 25 - Product Code JAK 26

Product

NeuViz 64 Multi-slice CT Scanner Systems

Code Information

NeuViz 64e, NeuViz 64i with software version 1.0.6.3258 +P04 or previous version.

NeuViz 64En, NeuViz 641n with software version 1.0.7.4021+P05 or previous version

Recalling Firm/

Neusoft Medical Systems Co., Ltd.

Manufacturer

NO. 16 Shiji Road Hunnan Industrial Area Shenyang China

For Additional Information Contact

281-453-1205

Manufacturer Reason for Recall

The Firm discovered during contrast agent tracking scan, when the expected concentration of contrast agent is reached, later planned scan may be interrupted. The system must be powered down and restarted to clear the interruption error before scanning can resume.

FDA Determined Cause 2

Software design

Action

Neusoft Medical Systems Co. Ltd. planned action to bring into compliance. 1.Affected Customers will be notified by letter to provide them a description of the affected device, instructions for using the device prior to correction, hazards associated with the defect, and a statement of corrective actions to be taken at no cost to the owner. 2. Field Service Engineers will visit owner sites to install a software update which resolves the defect. 3. Corrections will be made at no cost to the owner 4. Corrections will be completed by May 11, 2017. CDRH approves the CAP subject to the following conditions: .Notification of all dealers and purchasers is to be made within 15 working days of receipt of this letter in the manner specified in 21 CFR 1003.21 and 1003.22. This office and the Food and Drug Administration (FDA) district office coordinator noted below are to be included in the notification. Further questions please call (281) 453-1205.

Quantity in Commerce

23 units

Distribution

US Distribution

Total Product Life Cycle

TPLC Device Report²⁷